Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China; The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province, China; Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu Province, China; Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province, China.
Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China; The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province, China; Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu Province, China; Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province, China.
Hellenic J Cardiol. 2017 May-Jun;58(3):190-193. doi: 10.1016/j.hjc.2016.12.003. Epub 2016 Dec 20.
Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against cancer have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her cancer but die due to heart failure. Recent research has been focused on the development of new avenues and technological advancements to monitor clinical cardiotoxicity and cardiac dysfunction due to anticancer treatment. These newer treatment options are also increasingly effective and are focused more on post-cancer life. The present review article expands the current view of cardiac complications involved in cancer treatment along with the recent developments in the area.
心脏功能障碍通常与有效的癌症治疗有关。一些针对癌症的靶向治疗已被观察到会导致心脏功能障碍。在某些情况下，患者可能会战胜癌症，但最终因心力衰竭而死亡。最近的研究集中在开发新途径和技术进步上，以监测由于抗癌治疗引起的临床心脏毒性和心脏功能障碍。这些更新的治疗选择也越来越有效，并且更多地关注癌症治疗后的生活。本文综述扩大了目前对癌症治疗相关心脏并发症的认识，并介绍了该领域的最新进展。
